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Abstract
Background Radiofrequency ablation is safe and effective for complete eradication of nondysplastic Barrett esophagus
(BE). The aim was to report the combined results of two published and two ongoing studies on radiofrequency ablation of
BE with early neoplasia, as presented at SSAT presidential plenary session DDW 2008.
Methods Enrolled patients had BE ≤12 cm with early neoplasia. Visible lesions were endoscopically resected. A balloon-
based catheter was used for circumferential ablation and an endoscope-based catheter for focal ablation. Ablation was
repeated every 2 months until the entire Barrett epithelium was endoscopically and histologically eradicated.
Results Forty-four patients were included (35 men, median age 68 years, median BE 7 cm). Thirty-one patients first
underwent endoscopic resection [early cancer (n=16), high-grade dysplasia (n=12), low-grade dysplasia (n=3)]. Worst
histology remaining after resection was high-grade (n=32), low-grade (n=10), or no (n=2) dysplasia. After ablation,
complete histological eradication of all dysplasia and intestinal metaplasia was achieved in 43 patients (98%).
Complications following ablation were mucosal laceration at resection site (n=3) and transient dysphagia (n=4). After
21 months of follow-up (interquartile range 10–27), no dysplasia had recurred.
Conclusions Radiofrequency ablation, with or without prior endoscopic resection for visible abnormalities, is effective and
safe in eradicating BE and associated neoplasia.
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Introduction
Barrett esophagus (BE) is a condition characterized by a
change of the normal squamous esophageal lining into a
columnar epithelium containing specialized intestinal meta-
plasia (IM), due to longstanding exposure to gastro-
esophageal refluxate.1,2 BE is the best-recognized risk factor
for the development of esophageal adenocarcinoma, and
patients diagnosed with nondysplastic BE are, therefore,
advised to undergo endoscopic surveillance with biopsies
every 1 to 3 years.3 By histological evaluation of these
biopsies, malignant progression to low-grade dysplasia
(LGD), high-grade dysplasia (HGD), or early cancer (EC)
may be detected.1,2 Early neoplasia (i.e., HGD and/or EC)
can be treated by surgical esophagectomy. Given the
morbidity and mortality that may be associated with
esophagectomy, less invasive endoscopic alternatives have
been considered. Endoscopic resection (ER) is the corner-
stone of endoscopic therapy, since it provides a relatively
large tissue specimen for histopathological evaluation,
enabling proper selection of patients for subsequent endo-
scopic versus surgical therapy.4–6 Selected patients with
HGD or EC limited to the mucosal layer (T1m) have a
minimal risk of lymphatic involvement, and ER in these
patients has been reported to have a 5-year disease-specific
survival of 95%.5 Patients with submucosal invading lesions
(T1sm), however, have a 15–30% risk of lymphatic
involvement, warranting surgical esophagectomy with resec-
tion of surrounding lymph nodes.7,8
After focal ER of HGD/EC, the residual BE still holds
the potential of malignant degeneration, and metachronous
lesions occur in 30% of patients.9 Additional treatment of
the residual BE after focal ER is therefore advocated, and
different treatment modalities have been proposed for this
end. The residual BE may be completely removed with
stepwise radical endoscopic resection (SRER).10–12 This
approach allows for histopathological evaluation of the
entire BE segment and removes all oncogenetic alterations
that are present in the pretreatment BE.13 SRER, however,
is technically demanding, only amendable for patients with
a BE <5 cm, and has a significant stricture rate.10–12
Ablating the residual BE with argon plasma coagulation
(APC) or photodynamic therapy (PDT) has also been
described, but these techniques do not always result in
complete eradication of all Barrett epithelium, preexisting
oncogenetic alterations may still be found in residual areas
of BE, and both techniques are associated with issues of
variable ablation depth and safety.14–19 Furthermore, after
APC and PDT, areas of IM may become hidden underneath
the newly formed squamous epithelium after ablation (a.k.
a., “buried Barrett”), and some fear that these buried glands
may progress to dysplasia and adenocarcinoma without
being detected endoscopically.20,21 Stepwise circumferen-
tial and focal radiofrequency ablation (RFA) using the
HALO system is a novel and promising ablative modality.
Primary circumferential ablation is performed using a
balloon-based bipolar electrode, while secondary treatment
of residual BE is performed using an endoscope-mounted
bipolar electrode on an articulated platform. Studies
involving circumferential ablation were initially conducted
in the porcine animal model and in humans prior to
esophagectomy in order to determine dosing and technique
parameters.22–24 Subsequently, RFA has been proven safe
and effective for the eradication of dysplasia and IM in a
number of clinical trials involving patients without dyspla-
sia, with LGD or HGD, and after ER of EC and visible
lesions.25–27 In addition, no buried Barrett glands have been
found in over 4,000 neosquamous biopsies obtained during
follow-up,25–27 oncogenetic abnormalities as present in the
pretreatment BE are absent in the regenerated neosquamous
epithelium after RFA,28 and the functional integrity of the
esophagus is not affected by RFA.29 In this paper, we will
present the results reported in Abstract 215, which was
selected for oral presentation during the SSAT presidential
plenary A session, at the Digestive Disease Week 2008, San
Diego, CA, USA.30 We will review our results, as available
up until November 30, 2007, of stepwise circumferential
and focal ablation in 44 patients with BE and HGD/EC,
who were consecutively treated in four different, IRB-




Starting July 2005, patients between 18 and 85 years old
were consecutively included in a series of IRB-approved
clinical protocols evaluating the effect of RFA on BE with
early neoplasia, and conducted at the Academic Medical
Center, Amsterdam, the Netherlands. Patients were eligible
if they had endoscopically visible BE (≤12 cm) with HGD
or EC diagnosed at two separate endoscopies by an
experienced gastrointestinal pathologist (FtK). Any visible
endoscopic abnormalities, or EC without a clear lesion
detected by biopsies, were removed with ER prior to
ablation, as per the protocol. In case of prior ER,
histological evaluation of the specimen could not show
vertical resection margins positive for cancer (R+), deep
submucosal invading cancer (>T1sm1), poorly or undiffer-
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entiated cancer (G3, G4), or presence of lymphatic/vascular
invasion (V+). Patients with esophageal stenosis at baseline
and patients with invasive cancer in biopsies obtained after
ER but prior to RF ablation were also excluded. Our four
serial and unique study protocols were as follows:
1. The first prospective study on circumferential RFA of
HGD/EC in patients with a median BE segment of
5 cm [interquartile range (IQR) 5–7] using the
HALO360 ablation catheter, with prior en-bloc ER of
visible lesions and EC. Halfway through this study, the
focal HALO90 ablation device became available.26
2. The second prospective study on RFA for the treatment
of HGD and EC in patients with a median BE length of
7 cm (IQR 6.5–8) had a study protocol similar to the
first study. Based on the experiences from the first trial,
however, the protocol for this second trial had been
optimized by thorough cleaning of the ablation zone
and electrode surface in between ablation cycles, and
the focal HALO90 device was available from the start
of the study. In addition, patients with prior piecemeal
ER of visible lesions were also included.27
3. The first ongoing European multicenter trial to evaluate
the safety and efficacy of RFA in patients with a Barrett
segment up to 12 cm long, with early neoplasia, with or
without prior ER.31
4. An ongoing prospective randomized multicenter trial
comparing SRER and RFA for the eradication of
dysplasia and IM in patients with a BE <5 cm
containing early neoplasia.
Endoscopic Procedures and Medication
All endoscopic procedures were performed on an outpatient
basis using intravenous conscious sedation comprised of
midazolam and/or fentanyl. After the procedure, patients
were clinically observed for 2–4 h before they were
discharged. All patients were prescribed high-dose proton
pump inhibitors (i.e., esomeprazole 40 mg bid) as a
maintenance dosage during the entire study period. Sucralfate
suspension 5 mL (200 mg/mL) qid and ranitidine 300 mg
before bedtime were prescribed for 2 weeks after each
therapeutic endoscopy. In case of postprocedural discomfort,
patients were allowed to take acetaminophen 500 mg (max.
6/24 h), and if this did not suffice, diclofenac suppositories
100 mg bid were permitted.
Endoscopic Ablation Systems
Both ablation systems that were used (HALO Ablation
Systems, BÂRRX Medical, Sunnyvale, CA, USA) have
510(k) clearance by the Food and Drug Administration in
the USA and the CE Mark for Europe for the treatment of
BE. The HALO ablation system comprises two distinct
ablation systems: the HALO360 system for primary circum-
ferential ablation and the HALO90 system for secondary
focal ablation. The HALO360 system includes an energy
generator, ablation catheters, and sizing catheters. The
HALO360 energy generator delivers radiofrequency (RF)
energy to the electrode and has an integrated pressure–
volume system to inflate the sizing balloon and automat-
ically measure the inner esophageal diameter. The sizing
balloon catheter consists of a 4-cm noncompliant balloon
that is used for measuring the inner esophageal diameter of
the targeted portion of the esophagus, prior to circumfer-
ential ablation. The sizing catheter is introduced over a
guide-wire and its balloon is inflated in an automated
manner to 4 psi (0.28 atm). Based on the baseline balloon
volume–geometry and the volume needed to inflate the
balloon to 4 psi, the mean esophageal inner diameter is
calculated. Measurement is repeated moving distally, for
every centimeter of the targeted esophagus, until an
increase in diameter indicates the transition to the stomach
or hiatal hernia. The HALO360 ablation catheter has a
balloon at its distal end that is completely encircled by 60
electrode rings that alternate in polarity, over a length of
3 cm. The HALO360 ablation balloon is available in five
outer diameter sizes (22, 25, 28, 31, and 34 mm). Extensive
dosimetry studies in the porcine esophagus and human
esophagus prior to surgical esophagectomy have shown
that, for circumferential ablation, two applications of RF
energy at 10–12 J/cm2 and 40 W/cm2 is the most effective
regimen to ablate the full thickness of the epithelial layer,
without injuring the submucosa. Focal ablation of residual
BE tissue was performed with the HALO90 system. The
HALO90 system consists of the focal ablation catheter and
an energy generator. The bipolar electrode array of the
HALO90 catheter is 20 mm long and 13 mm wide and is
mounted on an articulated platform that can be attached to
the tip of an endoscope with a flexible strap. The electrode
array geometry and spacing are identical to those of the
balloon-based electrode (Fig. 1).
Endoscopic Work-Up
Prior to ablation, all patients underwent at least two high-
resolution endoscopies with narrow band imaging (NBI)
(GIF-Q240Z, Lucera 260 system, Olympus, Tokyo, Japan, or
GIF-H180, Excera II-system and a high-definition monitor,
Olympus Europe, Hamburg, Germany) to have the BE
segment thoroughly inspected by an expert endoscopist. The
maximum length of the circumferential and contiguous
Barrett epithelium was recorded according to the Prague
classification system.32 The maximum proximal extent of the
Barrett mucosa (i.e., isles) was additionally documented, as
isolated islands are not categorized in the Prague system.
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Visible lesions were classified in concordance with the Paris
classification; type 0-I being polypoid, type 0-IIa slightly
elevated, type 0-IIb flat, type 0-IIc depressed, and type 0-III
excavated.33 Biopsies were obtained from all visible lesions
detected upon white light endoscopy or by advanced
imaging techniques (NBI, autofluorescent imaging), and
random four-quadrant biopsies were taken every 1–2 cm of
the whole BE segment. To assess infiltration depth of lesions
and lymph node involvement, all patients underwent
endoscopic ultrasound (EUS) using electronic radial endo-
scopes (GF-UE160, Olympus GmbH, Hamburg, Germany)
in conjunction with an Aloka SSD-5000 ProSound processor
(Aloka, Meerbusch, Germany). In addition, computed
tomography scanning of thorax and upper one-third of the
abdomen was performed in all patients with EC to detect any
metastatic disease.
ER Procedures
All visible lesions and EC were removed with ER prior to
ablation. The objective of the ER was twofold. Firstly, ER
allowed for histological evaluation and staging, enabling
optimal selection of patients eligible for endoscopic treat-
ment. Secondly, ER of visible lesions ensured that the
subsequent ablation could be performed on an endoscopi-
cally flat mucosa. ER was performed using the ER-cap
technique (Olympus GmbH) after submucosal lifting, or the
multiband mucosectomy (MBM) technique (Duette™, Cook
Endoscopy, Limerick, Ireland). Lesions with a diameter
<2 cm were resected en-bloc; larger lesions were resected in
multiple pieces (piecemeal procedure). All resected speci-
mens were retrieved, pinned down on paraffin, and fixed in
formalin for histopathological evaluation.
Endoscopic Ablation Procedures
For primary circumferential ablation, the esophageal wall
was sprayed with acetylcysteine (1%) and flushed with
plain water to remove excessive mucous. After recording
the esophageal landmarks (i.e., top gastric folds, maximum
extent of BE), the endoscope was removed, leaving a
guide-wire (Amplatz extra stiff 0.035 in., Cook, Denmark,
Europe) behind. A sizing balloon was introduced and the
inner esophageal diameter was measured for every centi-
meter of the targeted BE segment, moving proximally to
distally. Based on the measurements, an ablation catheter
with an appropriate outer diameter was selected. The
ablation catheter was introduced over the guide-wire,
followed by the endoscope to allow the ablation procedure
to be performed under endoscopic guidance. The electrode
was placed 1 cm above the maximum proximal extent of
the BE, the balloon was inflated, and the electrode was
activated (12 J/cm2, 40 W/cm2). This resulted in a 3-cm-
long, circumferentially ablated segment. Depending on the
length of the BE segment, the ablation catheter was
advanced and, allowing an overlap of 5–10 mm, reposi-
tioned distal to the first ablation zone. Ablation was
repeated until the entire length of the BE segment had
received one application of energy. Then, the ablation zone
and electrode surface were cleaned. In the first 11
patients,26 cleaning was performed by advancing the
ablation balloon into the stomach, where it was inflated
and flushed with water through the endoscope to rinse off
excessive coagulum. The ablation zone was also rinsed
with water through the spraying channel of the endoscope.
For the next 12 patients,27 the ablation catheter was
removed and the electrode surface was cleaned outside the
patient. The ablation zone was more rigorously cleaned
compared to the first trial by forcefully spraying water
through a spraying catheter using a pressure pistol
(Alliance™, Boston Scientific, Limerick, Ireland, UK). In
the following patients, cleaning was optimized by the use of
a soft distal attachment cap fitted on the tip of the
endoscope that was used to slough off most of the
coagulum from the ablation zone, prior to forceful rinsing
with water through a spraying catheter. After the cleaning
procedure, the entire ablation zone was ablated a second
time, using the same energy settings.
For secondary focal ablation with the HALO90 system, the
mucosa was sprayed with acetylcysteine (1%) and flushed
with plain water. The HALO90 electrode was fitted on the tip
of the endoscope, introduced, and used for targeted ablation
Figure 1 The HALO ablation
system used for circumferential
and focal RFA of BE. Left: The
HALO360 generator and HA-
LO360 ablation catheter used for
primary circumferential
ablation. Right: The HALO90
ablation catheter fitted on the tip
of an endoscope, for secondary
focal ablation.
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of residual Barrett epithelium. The squamocolumnar junction
was routinely ablated when the HALO90 electrode was
introduced to ablate residual isles or tongues. The HALO90
system only became available at the end of the first trial, and
the energy settings were escalated from 2×12 to 2×2×
12 J/cm2 and, eventually, to 2×2×15 J/cm2 at 40 W/cm2. All
areas were ablated with cleaning of the electrode and ablated
area in between ablation cycles, as previously described for
the circumferential ablation procedure.
Treatment Protocol
After a minimum of 6weeks after any ER, patients were treated
with primary circumferential ablation using the HALO360
system. After 6 to 8 weeks, patients were scheduled for
endoscopy to assess the treatment effect. Depending on the
extent of residual BE, patients underwent a second HALO360
procedure, or secondary focal ablation using the HALO90
system. In the first study protocol, all patients were treated
with a second circumferential ablation using the HALO360
system, regardless of the extent of the residual BE, since the
HALO90 system for focal ablation was only introduced
halfway through the study.26 Additional ablation was repeated
every 6–8 weeks, and a maximum number of two circumfer-
ential and three focal ablation sessions were allowed to
achieve complete eradication of all IM. Persisting IM after the
maximum number of ablations could be endoscopically
resected using the MBM technique. Two months after the
last treatment session, the endoscopic eradication of IM was
assessed during endoscopy using high-resolution endoscopes
with Lugol’s staining (2%) or narrow-band imaging. To
assess the histological clearance of IM, biopsies were
obtained from four quadrants just distal to the neosquamoco-
lumnar junction and every 1–2 cm from the neosquamous
epithelium over the full length of the initial BE segment.
Follow-up
Patients were scheduled for follow-up endoscopy 2, 6, and
12 months after the last treatment session and then
annually. High-resolution endoscopes with narrow-band
imaging facilities were used to thoroughly inspect the
esophagus for recurrence of IM, and four-quadrant biopsies
were obtained for every 1–2 cm of the neosquamous
epithelium over the original BE length and immediately
distal to the neosquamocolumnar junction. Patients initially
treated for EC underwent EUS every 12 months to exclude
the presence of lymph node metastases.
Histopathological Review
All biopsies and ER specimens were embedded in paraffin,
mounted on glass slides, and routinely stained with hemotox-
ylin and eosin. For the purpose of the described studies, all
slides were reviewed by an expert GI-pathologist (FtK). The
ER specimens were evaluated for the presence of dysplasia
according to the revised Vienna classification,34 tumor infiltra-
tion depth, tumor differentiation grade, presence of lymphatic
or vascular infiltration, and the radicality of the resection at the
deep resection margins. Biopsies were evaluated for the
presence of IM, LGD, HGD, or EC, and in case of
neosquamous biopsies, the presence of glandular mucosa
underneath the neosquamous epithelium was assessed.
Ethical Considerations and Statistical Analysis
The Medical Ethics Committee at our institute approved all
aforementioned study protocols, and written informed consent
was obtained from all included patients. Statistical analysis
was performed with SPSS 12.0.1 Software for Windows. For
descriptive statistics, mean (±SD) was used in case of a normal
distribution of variables and median (IQR) was used for
variables with a skewed distribution. Where appropriate, the
student t test and the Mann–Whitney test were used.
Results
Patients
A total of 44 patients was enrolled in the different study
protocols, and all had finished treatment by 30 November
2007: 35 men, median age 68 (IQR 57–75) years, median
Barrett length C5M7 (IQR C2–7, M4–9). Eleven patients
were included in the first published trial on RFA,26 12
patients in the second published trial,27 nine patients in the
ongoing European multicenter trial,31 and 12 patients were
randomized to RFA in the ongoing randomized trial
comparing RFA with SRER. A total of 36 ER procedures
were performed in 31 patients prior to ablation. Nineteen
were performed with the ER-cap technique after submuco-
sal lifting and 17 with the multiband mucosectomy
technique. There were 16 en-bloc and 20 piecemeal
resections, with a median of two pieces per resection
(IQR 2–3). The worst histological grade per patient found
in the ER specimens was EC in 16 patients, all radically
resected at the deep resection margin, HGD in 12 patients,
and LGD in three patients. The worst histological grade of
the BE after any ER, but prior to the first ablation
procedure, was HGD in 32 patients, LGD in 10 patients,
and residual nondysplastic IM in two patients.
Eradication of Dysplasia and IM
Complete histological eradication of dysplasia and complete
endoscopic and histological clearance of IM was achieved in
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43 patients (98%), after a median of one (IQR 1–2) cir-
cumferential ablation, two (IQR 1–2) focal ablation sessions,
and escape ER in three patients (Fig. 2). These three patients
had small areas of residual columnar epithelium that
persisted after the maximum number of allowed ablation
sessions. These areas were resected using the MBM
technique and showed LGD (n=2) and HGD (n=1) upon
histological evaluation. In one patient, the proposed treat-
ment protocol failed (2%). After two ER sessions, one
circumferential and two focal ablations, a persisting area of
suspicious-looking columnar epithelium was observed and
resected en-bloc using the MBM technique. Histology showed
a T1sm1 adenocarcinoma, radically resected at the deep
resection margins (R0). Two months after the escape ER,
however, a suspicious 5-mm isle was identified. Additional
resection of this area failed due to scarring resulting from the
prior ER sessions. Since the patient strongly opposed surgical
treatment, the area was ablated with APC (forced coagulation
60 W, gas flow 1.6 L/min, ERBE Vio System, Erbe
Elektromedizin GmbH, Tübingen, Germany). Two subsequent
follow-up endoscopies with extensive biopsies and EUS
showed no signs of recurrent dysplasia or IM.
Adverse Events
In five patients, a complication occurred during ER (16%):
there were four mild bleedings that could be easily
managed with endoscopic hemostatic techniques and there
was one esophageal perforation. The perforation was
treated conservatively by placement of clips (resolution
clips, Boston Scientific), and a covered esophageal stent
(Esophageal Choo Stent, Fujinon Medical Holland B.V.,
Veenendaal, the Netherlands). In addition, the patient
received immediate intravenous administration of anti-
biotics and acid suppressant therapy, an esophageal tube
for suction and nil per mouth. He remained asymptomatic
and no signs of leakage were seen on contrast swallowing
examination. After 2 months, the defect had completely
healed and treatment could be resumed. After initial
circumferential ablation, a nontransmural laceration was
Figure 2 Endoscopic treatment of a C8M9 BE with HGD and a visible
lesion treated with a combination of ER and RFA using the HALO system.
A Antegrade view on a C8M9 BE. B View on a 0-I–IIa lesion at the 5
o’clock position. C View on the resection wound. The specimen showed a
submucosal cancer with radical vertical and lateral resection margins.
D Same area 6 weeks after the ER. The wound has healed completely
with scarring. E HALO360 ablation balloon positioned 1 cm above the
maximum extent of the BE. F Ablation effect after cleaning off the
coagulum. G Residual isle of Barrett mucosa remaining 6 weeks after
prior circumferential ablation. H Effect immediately after ablation with the
focal ablation device. I Complete removal of he whole Barrett segment
mucosa after one ER and two ablation sessions. J Corresponding
image with NBI. K neosquamocolumnar junction after treatment.
L Corresponding image with NBI.
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observed in three patients (7%). All patients remained
asymptomatic and no therapeutic interventions were re-
quired. The lacerations all occurred at the level of the ER
scar in patients were an ablation catheter with a relatively
large diameter was selected in relation to the esophageal
inner diameter and who had undergone prior ER with a
median extent of 33% of the circumference and 2.5 cm in
length. Four patients (9%) developed dysphagia after
ablation that could be resolved with a median of three
(IQR 1–5) endoscopic dilatations. These patients all had
prior widespread ER [median of three (IQR 1–5) pieces per
procedure, 50% of the circumference and 2 cm in length],
two had undergone two ER sessions, and one patient had a
narrow esophagus at baseline. No lacerations or stenoses
were observed in patients after ablative therapy if they had
not had prior ER. Four patients (9%) were hospitalized after
primary circumferential ablation for observation of fever
(n=1), chest pain (n=2), and superficial mucosal laceration
at a previous ER site followed by a negative contrast study
(n=1). After conservative treatment and analgesics, all were
discharged after 24–48 h.
Follow-up
During a median follow-up of 21 (10–27) months, no
recurrence of dysplasia was observed. In one patient, a
1-mm BE island was identified 16 months after the last
treatment, located at the upper end of the initial C9M10
Barrett segment; none of the other 43 patients showed
endoscopic signs of BE during follow-up. Five patients had
focal IM detected in biopsies obtained immediately distal to
an endoscopically normal appearing neosquamocolumnar
junction at a single follow-up endoscopy. In 1,475 biopsies
obtained from neosquamous epithelium, only one (0.07%)
showed buried glandular mucosa.
Discussion
This manuscript reviews our interim results of RFA for BE
with early neoplasia from four different study protocols at
the Academic Medical Center, Amsterdam, the Nether-
lands, and was written to accompany our oral presentation
during the SSAT presidential plenary A session, at the
Digestive Disease Week 2008.30 A total of 44 consecutive
patients with BE containing HGD and/or EC had finished
treatment by November 30, 2007. Of these, 23 patients
were treated in the first two pilot studies worldwide to
evaluate the use of stepwise circumferential and focal
ablation of BE with HGD/EC after prior ER of any visible
abnormalities and EC.26,27 The other 21 patients were
included for the first European multicenter study on RFA of
BE up to 12 cm containing HGD/EC,31 or in an ongoing
study comparing SRER with RFA in patients with early
neoplasia in BE<5 cm. In all four studies, it was
protocolized that any visible lesions and EC had to be
removed with ER prior to ablation to enable histological
evaluation for accurate staging of the infiltration depth and
tumor differentiation and to ensure that subsequent RFA
could be performed on an endoscopically flat mucosa. In
the first study, six of the 11 patients had undergone an en-
bloc resection of a visible lesion. No significant esophageal
scarring was observed in these patients, and no complica-
tions such as mucosal injury or dysphagia occurred after
ablation treatment. In the other three studies, patients with
prior piecemeal ER or multiple ER sessions were included,
and mucosal injuries (n=3) and dysphagia (n=4) were
observed for the first time. The four patients presenting
with dysphagia had all undergone widespread ER and/or
were treated with a relatively large-diameter ablation
catheter compared to the measured esophageal diameter.
To prevent complications resulting from ER scarring, it is in
our opinion that one should limit the extent of ER of visible
lesions to 50% of the circumference and 2 cm in length. In
addition, the HALO360 ablation catheter size should be
selected conservatively in cases of prior ER, preferably one
size smaller than the catheter that would be selected based
on the esophageal inner diameter measurements. No
esophageal stenoses were observed in patients without a
prior ER who were exclusively treated with ablation
therapy. These results are in concordance with the USA
multicenter ablation of IM study, where no strictures were
reported in 100 patients treated with RFA.25 The absence of
submucosal scarring as a result of RFA was also illustrated
by our ability, in three patients, to remove focal areas of
persistent Barrett mucosa after multiple ablation sessions
using the multiband mucosectomy technique, without the
need for submucosal lifting in three patients. This is a
significant advantage compared to other endoscopic abla-
tion techniques, after which escape treatment using ER is
usually difficult as a result of submucosal scarring. In the
1,475 biopsies obtained from neosquamous epithelium
during follow-up, only one biopsy showed focal IM hidden
underneath the newly formed squamous epithelium. This
biopsy was obtained at the upper end of an initial C9M10
Barrett segment, at the same level where, at a following
endoscopy, a small 1-mm isle was identified with narrow-
band imaging that may have been left untreated and
unobserved at the preceding endoscopies. The fact that no
buried glands were found in eight biopsies obtained at this
level during other follow-up endoscopies, and the absence
of any IM in an ER specimen to remove the 1 mm isle,
suggests that the biopsy with buried IM may have sampled
this minute isle tangentially, rather than sampling truly
buried Barrett glands. Although this hypothesis cannot be
confirmed, the 0.07% of subsquamous IM still compares
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favorably to the 53% rate of buried glands reported after
other ablation techniques.14–21 Our findings were in
concordance with the absence of buried glands in 3,007
neosquamous biopsies after RF ablation in the 100 patients
described by Sharma et al.25 Further studies on the
adequacy of biopsies from the neosquamous epithelium
after RFA should, however, clarify this issue further.
Ablation at the GE-junction using the HALO360 catheter
may be difficult, since the often tortuous course of the distal
esophagus and widening into a hiatal hernia, present in
most BE patients, may impede good circumferential contact
of the electrode with the mucosa at this level. In addition,
endoscopically differentiating cardia mucosa from Barrett
mucosa at the top of the gastric folds after ablation
treatment may be difficult. Therefore, all patients were
treated with ablation of the GE-junction using the HALO90
catheter. The HALO90 device allows for targeted, focal
ablation and was used to completely ablate the full
circumference of the GE-junction to ensure that there was
no small rim of residual Barrett mucosa left untreated at the
transition of the columnar epithelium into the neosquamous
epithelium. Despite this approach, focal IM was diagnosed
in five patients (11%) in a single biopsy obtained just distal
to a normal appearing neosquamocolumnar junction at a
single follow-up endoscopy, not reproduced at following
endoscopies. The clinical relevance of this finding may be
debated. Since all patients had an initial diagnosis of HGD
or EC, one may argue that finding residual IM in the cardia
during follow-up means that the IM had not been
completely eradicated and that the patients were not
completely cured from their underlying disease. IM of the
cardia, however, can be detected in up to 25% of patients
with a normal appearing squamocolumnar junction and is
not considered a premalignant condition in those cases.35 In
addition, we think that the patchy nature of this finding, and
the fact that all patients will remain under endoscopic
follow-up given their initial diagnosis of HGD/EC, does not
justify additional treatment. As described in the “Materials
and Methods” section, the treatment protocol for the second
trial was improved based on the experiences from the first
trial. These improvements were reflected in the median
number of treatment sessions required to achieve complete
eradication of IM. Although the median BE length was
longer in the second trial [7 cm (IQR 6.5–8) vs. 5 cm (IQR
4–7)], the mean number of ablation sessions was lower (3.4
vs. 4.2 sessions). The three most significant changes in the
protocol were as follows: firstly, the HALO90 catheter for
secondary focal ablation only became available halfway
through the first trial. Most patients had by then already
undergone a second circumferential ablation session,
regardless of the amount of residual BE, whereas in the
second trial, the HALO90 device could be used to treat isles
or tongues persisting after the first circumferential ablation.
Secondly, the energy settings used for focal ablation were
escalated from two ablations at 12 J/cm2, to two times two
ablations at 12 J/cm2 (“double-double”), to double-double
15 J/cm2 when the device became available during the first
trial. In the second trial, the double-double 12 J/cm2 dose
was used initially, but in four patients, a step-up to double-
double 15 J/cm2 ablation was required to eradicate all IM.
Since this “double-double 15 J/cm2” approach proved
effective without causing significant side effects, this dose
is currently used in the ongoing studies. Thirdly, in the first
study, the electrode surface of the HALO360 catheter was
cleaned by inflating the balloon in the stomach and flushing
it with water prior to the second ablation pass, without
significant cleaning of the ablation zone. In the second trial,
the electrode surface was cleaned with a wet gauze outside
the patient, while the ablation zone was thoroughly cleaned
by suctioning off the debris and high-pressure rinsing with
water through a spraying catheter. The effect of this
improved cleaning protocol was observed in the amount
of surface regression after the primary circumferential
ablation session; the median percentage of surface regres-
sion improved from 90% in the first trial to 99% in the
second trial (p=0.035).36 We think that, although it requires
additional procedure minutes, meticulous cleaning of the
electrode and ablation zone after the first pass improves
the efficacy of RFA and should always be performed. The
thorough cleaning protocol has, therefore, been incorporated
in current trials.
Conclusion
Stepwise circumferential and focal RFA of Barrett epithe-
lium with HGD or EC, with or without prior ER of focal
lesions, is highly effective in achieving complete eradica-
tion of dysplasia and IM, without any serious adverse
events. This novel treatment modality, therefore, appears to
be a favorable alternative to esophagectomy, radical ER,
APC, or PDT.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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Discussion
Eradication of Barrett Esophagus with Early Neoplasia
by Radiofrequency Ablation, With or Without Endoscopic
Resection
Jeffrey H. Peters, M.D. (Rochester, NY)
Members and guests, I believe we have just heard what I
would call a paradigm changing paper. The search for a
treatment for the epithelial changes of Barrett’s, as opposed
to the reflux related disease, has been ongoing for more than
two decades. Drug therapy, surgery, a multitude of ablation
technologies, thermal energy, laser, photodynamic therapy,
all of these have fallen well short of the safety and
effectiveness necessary for everyday clinical use. Radio-
frequency ablation, however, seems poised to change this
paradigm.
The authors have reported successful endoscopic mucosal
resection followed by RF ablation in a relatively large cohort
of patients with Barrett’s and high grade dysplasia and/or
early neoplasia. Successful eradication, as you heard,
occurred in 43 of the 44 patients. There are a few caveats,
however, that deserve highlighting. Firstly, remember, this is
not a trial of RF ablation alone. Three quarters of the patients
had mucosal resection prior to the RF; also, a very careful
patient selection protocol was necessary to exclude those
with submucosal cancer, a key issue; and finally, the
longevity of the ablation is unknown at present. On the
other hand, ablation was highly effective, successful, and
was not associated with the development of strictures or
buried submucosal glands.
This technology, this study, and others like presented at
this meeting. Are changing the treatment paradigm of
dysplastic Barrett’s esophagus and early cancer. This is an
excellent and well done study from one of the world’s best
units treating early esophageal neoplasia.
Jacques, I have a few brief questions for you. Firstly,
visible lesions were key to the EMR technique. Most visible
lesions are submucosal. You excluded all submucosal
lesions. This suggests to me a very highly select patient
population. Further, you didn’t mention whether you had any
patients with cancer on their biopsy that did not have visible
lesions and what you would do under those circumstances.
Surely you encountered such patients. Would you suggest
how to approach these?
Second, ablation at the gastroesophageal junction may be
an Achilles’ heel of this technology. Reading the manuscript,
Jacques has chosen to ignore biopsies right at the top of the
stomach in the efficacy assessment. I would like for you to
comment on this issue.
Finally, although your 98% success rate is spectacular,
more widespread experiences suggest that it may not be quite
this easy. Has your near uniform success continued as your
experience has grown?
This is a wonderful contribution from the Amsterdam
group and it is really a pleasure to see it presented here at the
SSAT. Thank you for the honor of discussing it.
Jacques J. Bergman, M.D. (Amsterdam, Netherlands)
ell, thank you, Jeff, for those questions and those kind
words. Coming back to your first question, are most visible
lesions submucosal, the answer is no. The vast majority of
visible lesions that we encounter are mucosal, but you bring
up an important issue: we should simply teach our endo-
scopists how visual abnormalities look like so that they
detect them at a stage that they are still mucosal. In our
study, we excluded approximately 15% of our patients after
EMR showed the resected lesion to be submucosal.
What do we do if we don’t see visual abnormalities? I
think that good endoscopic inspection is crucial before you
decide that there is nothing there. We have a very low
threshold of calling something a visual abnormality, and I
would urge everybody who steps into this technique to do
this. EMR is the crucial here: it is the final step in the
diagnostic work-up and it is the first step in therapy. If you
cannot do an EMR, you should not ablate. So if we didn’t
see any visual abnormalities, but as you said, it is only a
quarter of our patient population, then that patient is eligible
for immediate radiofrequency ablation.
The IM immediately distal to the neo Z line is a tough
issue. We had that happen in five of our patients who during
1636 J Gastrointest Surg (2008) 12:1627–1637
follow up had IM detected in a single biopsy that was
obtained immediately distal to the neo Z line. At subsequent
follow up endoscopies, this was not reproduced. I think it is
all reflecting sampling error. It will be very difficult to call an
end point for absence of IM at the Z-line. What to do if you
take biopsies at a certain point and you don’t find it and you
don’t find it at the second or the third follow up and it the
pops up at the fourth and the fifth and then again is absent at
the sixth, how do we call this? This is one of the issues that I
think we need to clarify if we define outcomes, and
especially if we go into the long term follow up of these
patients. You rightfully pointed out that we don’t have long
term follow up on these patients. We simply have to continue
looking at these patients to prove that the complete removal
of all Barrett’s is indeed maintained. If we look at oncogenetic
abnormalities, if we do brush cytology, if we do biopsies, then
we see that the neo squamous epithelium really is “clean,” in
that sense.
Experience, how did it change during our consecutive
studies? It maintained at the same level. We are presenting at
this meeting the first results of the European multicenter
study with three centers. The success rate for that was 96%.
We are currently doing a multicenter study with 11 European
centers, and we hope to present those data to you next year.
Stephen Attwood, M.D. (North Shields, UK)
Jacques, the real test of any new treatment is a
randomized controlled trial. Can you randomize between
EMR versus EMR and HALO, or can you randomize
between surgical resection versus EMR and HALO, and
what are the hurdles to setting up such a randomized trial?
Dr. Bergman: My presentation is competing with the
presentation of the results of a randomized sham controlled
study that is presented at the AGA plenary session. I think
the main issue is if you want to do randomized studies, at
least in the Netherlands, we have to do randomized studies
comparing endoscopic treatment with another endoscopic
treatment. Our Dutch guidelines state specifically that for the
patient category that we included in this study, endoscopic
treatment is the treatment of choice. So we could never do a
randomized study with a surgical arm for this group. I know
that in the U.K. there are thoughts about that, and of course,
it will be the ultimate proof. In the Netherlands, we have
moved beyond that. According to our guidelines, we don't
need more proof to treat these patients endoscopically.
John G. Hunter, M.D. (Portland, OR)
As surgeons, we were very happy to be part of the
randomized U.S. trial of radiofrequency ablation of HGD,
which will be presented at the AGA. The proof of this
therapy will be durability, and you have pointed out that 21
months is a little early to prove that the natural history of
HGD has been changed by this therapy. The second proof is
the elimination of sub-squamous glands, which have the
potential to become malignant. In your salvage EMR cases,
did you find sub-squamous glands beneath that beautiful
neo-squamous epithelium?
Dr. Bergman: The first 23 patients that were in our
studies, the first two studies that were published in
Endoscopy this month, were all called back the last two
months for an EMR of the neo squamous mucosa. So we
EMR'd a part of their neo squamous mucosa out. Sixteen
have been completed, and preliminary results don't show any
submucosal or sub squamous IM in any of these. We took
biopsies of the neo squamous mucosa and biopsies of
untreated epithelium and, blinded, gave them to two expert
pathologists asking them what is neo squamous and what is
normal squamous. They cannot tell the difference.?
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